Evidence map›Paper›PMID 24753753›Full record

ArticleInternational journal of clinical and experimental medicine2014

Effect of Tianshengyuan-1 (TSY-1) on telomerase activity and hematopoietic recovery - in vitro, ex vivo, and in vivo studies.

Su Lu, Xiaotian Qin, Shaopeng Yuan, Yawei Li, Liming Wang, Yusheng Jin, Gang Zeng, Lawrence Yen, Jenny Hu, Tracie Dang and 3 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Su LuDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles Los Angeles, CA, USA ; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University and Tianjin Medical University Cancer Institute and Hospital Tianjin, China.
Xiaotian QinBeijing Tianyuyiming Biological Technology Co., Ltd (BTBTL) Beijing, China.
Shaopeng YuanInstitute of Materia Madica, Chinese Academy of Medical Sciencese Beijing, China.
Yawei LiBeijing Tianyuyiming Biological Technology Co., Ltd (BTBTL) Beijing, China.
Liming WangDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles Los Angeles, CA, USA ; Department of Surgery, Cancer Hospital, Chinese Academy of Medical Science Beijing, China.
Yusheng JinDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles Los Angeles, CA, USA.
Gang ZengDepartment of Urology, David Geffen School of Medicine, University of California at Los Angeles Los Angeles, CA, USA.
Lawrence YenDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles Los Angeles, CA, USA.
Jenny HuDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles Los Angeles, CA, USA.
Tracie DangDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles Los Angeles, CA, USA.
Sophie SongDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles Los Angeles, CA, USA.
Qi HouInstitute of Materia Madica, Chinese Academy of Medical Sciencese Beijing, China.
Jianyu RaoDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles Los Angeles, CA, USA.
University of California, Los Angeles · USChinese Academy of Medical Sciences & Peking Union Medical College · CNTiande (China) · CNTianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aplastic anemia is a heterogeneous disorder of bone marrow failure syndrome. Accumulating evidence indicates that both acquired and congenital aplastic anemia is linked to telomerase activity and telomere length. Chinese herbal medicine Tianshengyuan-1 (TSY-1), a liquid extraction of multiple Chinese herbs, appears to stimulate hematopoiesis in patients with bone marrow deficiencies; however, the exact mechanism of action remains unclear. In this study, we investigated the effect of TSY-1 on telomere length and telomerase activity. We first investigated the effects of TSY on in vitro cultured cell lines including CD34+ hepatic stem cells and CD4+/CD8- Jurkat cells. An immune-mediated murine aplastic anemia model and human samples, including peripheral blood samples of 4 healthy donors and bone marrow hematopoietic cells from 4 patients with hypocellular myelodysplastic syndrome (MDS), were also used to test the efficacy of TSY on hematopoiesis, telomerase activity and telomere length. Our results indicated that TSY-1 increased the telomerase activity and telomere length in a dose-response manner in vitro, in vivo, and in human samples including 3 of 4 healthy individuals and 3 of 4 bone marrow samples from MDS patients. In immune-mediated murine aplastic anemia model, TSY-1 activity on Telomere length was parallel to the significant increasing of the RBC, hemoglobin, hematocrit, and platelet count in peripheral blood, increasing of CD34+ cell count and hematopoiesis, and decreasing of fatty infiltration in bone marrow samples. Our study demonstrated that TSY-1 may exert its effects by modulating telomerase activity of hematopoietic cells. Further studies are warranted to explore the precise molecular mechanisms of how TSY-1 regulates telomerase activity and telomere length, and also to test the TSY-1 in randomized control trials.

Indexed as

hematopoietic cellstelomerasetelomereTSY-1

Identifiers

PMID24753753
PMCPMC3992398
OpenAlexW2223923562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.